CHEN-HUA LIUJIA-HORNG KAO2021-09-042021-09-0420140003-4819https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898871454&doi=10.7326%2fL14-5008-4&partnerID=40&md5=3a3f5a130652b8bcac49684533ff1639https://scholars.lib.ntu.edu.tw/handle/123456789/581975[SDGs]SDG3boceprevir; peginterferon alpha2a plus ribavirin; telaprevir; virus RNA; alpha interferon; antivirus agent; macrogol derivative; ribavirin; anemia; asthenia; drug efficacy; drug safety; end stage renal disease; hemodialysis patient; hepatitis C; Hepatitis C virus genotype 1; human; letter; monotherapy; nonhuman; priority journal; treatment response; female; hepatitis C; male; note; renal replacement therapy; virology; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Renal Dialysis; Ribavirinletter10.7326/L14-5008-4247332082-s2.0-84898871454